Bio (midsize) and reasoning

I am the inventor and developer of tissue-biosensing of folliculogenesis in vivo, and a longtime biomedical entrepreneur. I am committed to commercialization of the Folliculogenesis In Vivo™ ovulographic™ (cervical tissue sensing) technology. Non-interventional (pseudo-)hormone-free reproductive management (i.e. sex life management) for women & diagnostic menstrual cycle vital sign profiles for doctors & insurance payers.

Tweetroducing bioZhena in 8 slides

Tweetroducing bioZhena in 8 slides

I am thinking: Evidence-based medicine, Personalized medicine, eHealth, Self-care.

Taking this well beyond https://biozhena.wordpress.com/2012/05/14/why-too-many-young-and-not-so-young-ladies-could-not-receive-flowers-on-mothers-day-why-so-many-trying-to-conceive-why-so-much-infertility/ and beyond https://biozhena.wordpress.com/2013/01/02/serious-health-consequences-of-delaying-pregnancy-and-the-need-for-prevention-of-impaired-fertility-also-known-as-subfertility-and-infertility/ .

Monitoring the menstrual cycle ovulographic™ signatures will be essential for patient profiling with which to manage women’s frequent menstrual and fertility, reproductive and general health problems. The menstrual cyclic profiles, recorded at home, are descriptive of reproductive cycling and relate to a woman’s well-being – somewhat similar to (though not as “granular” as) how EKG recordings pertain to the health of the heart.

There was a period of privately funded R&D before I founded bioZhena Corporation, and not without expenditures including blood, sweat and tears… which was not much different from the experience with my predecessor company CTI.

I had started CTI with my own funds (voluntary severance from Wellcome Foundation Ltd. plus 100% profit from house sale near London when they completed the orbital motorway and home appraisals within easy reach shot up), having started the biomedical technology project some years prior, out of the need to overcome a surprising difficulty to conceive a pregnancy. A son and a daughter proved that “sterile marriage” was a wrong diagnosis and that “the right time” was a key concept in female reproductive management.

I acquired experience with Private Placement Memorandum Offering (PPM, reg D) and private investing by non-accredited investors in Colorado (USA). Prior to this, I was for a decade Senior Research Scientist at the big-pharma firm Wellcome Foundation Ltd. (Glaxo-Wellcome, now GSK) in pharmaceutical bio-electrochemistry exploratory research; and before that a Research Fellow investigating electro-acupuncture at the City University of London, UK.

After the 5 mostly bootstrapping years with CTI, I realized that I was the inventor of tissue-biosensing of folliculogenesis in vivo. Earlier, we simply had a superior technique of predicting and also uniquely detecting ovulation, which was not understood by professional investors in those years before fertility problems became a medialized hot topic. My many private placement subscribers – mostly women – could see the superiority in the performance data. But trying to emulate the penny stock financing in the 1990s, by modeling (per a mentor’s guidance) on the 1960s success of the local predecessor of Teledyne Waterpik, was a bad mistake as it turned out. We learn from mistakes…

I was raised and educated initially in Prague (Praha) when it was still capital of Czechoslovakia. Having managed to get away from the then communist regime, I did my postgraduate work in the UK (PhD). Afterward, I was a postdoc in USA (Colorado) and in London.

I embarked on my entrepreneurial career after ten stimulating years in exploratory research at the big pharmaceutical company in the UK, and I emigrated with the venture and my young family to the US (kind of per Greeley’s dictum “go west, young man”).

See my and bioZhena Corporation’s mission at https://biozhena.wordpress.com/biozhenas-mission-a-health-tool-for-every-woman/ — and for her physicians. Do peruse this document if you are seriously interested in the project. Or in the subject matter.

For Assumptions of Our Minimum Viable Product Scenario go to https://biozhena.wordpress.com/assumptions-of-our-minimum-viable-product-scenario/ . But of course my purpose and ambition is really along the lines of the Full Value Scenario. The plan: https://biozhena.files.wordpress.com/2019/09/biozhena-ovulonae284a2-slide-presentation-201909-forpdf-1.pdf

bioZhena Corp. is pre-revenue and we seek the right investor. And I seek the right EVP/COO/successor CEO since I have aged somewhat too much with the project. Seeking for the role a person of either gender, and seeking a marketeress who will be the voice and face of the women’s healthcare technology Company. Some serious seeks!

Contact data: Email: vaclav AT biozhena DOT com .
Tel.: 970-484-1272 (please email to schedule the call, send your info). That is, provided that the above Tweetroducing slide deck resonates with you, and that you therefore also reviewed the therein-linked Transforming Women’s Reproductive Health Management set of 11 slides, most of them narrated by yours truly. In that case, so long, till we talk…

This page was brought here from https://gust.com/user/ece3a216494622d0b98cb771c668dc27 on September 26, 2019 (and touched up a bit afterwards).


%d bloggers like this: